| Revenue growth | 21.3% YoY; 8.4% QoQ |
|---|---|
| Margins | Gross margin 25.1%, down 110bps YoY, up 60bps QoQ |
| Demand visibility | Omni-channel revenue ₹111cr, about 5.5% of total |
Growth
Revenue +21.3% YoY, +8.4% QoQ; H1 revenue +21.6%. Operating EBITDA +10.7% YoY, margin down 50bps to 4.8%. Reported PAT +1.0% YoY.
Outlook
No explicit guidance. Net store additions of 166 in Q2; 1,600 outlets (<24M old) expected to become P&L accretive on maturity.
Risks
Gross margin down 110bps YoY to 25.1%. FCF -₹84cr. Inventory rose to ₹1,521cr. D&A up 22% YoY.
Last quarter's promises, checked
Delivered
- Upside 'in coming quarters' promised → Q2 op. EBITDA ₹98cr vs Q1 ₹65cr; margin 3.5%→4.8% (= BEAT)
Partly delivered
- Recover ~100bps GM lost to private-label mix → GM +60bps QoQ to 25.1% (= PARTIAL)
- 800 net store adds FY27 → Q2 net 166 (Q1 146); FY total not yet verifiable (= PARTIAL)
Missed
- Return to ~9% EBITDA margin (mgmt: 'target to go back to earlier reported numbers') → 4.8% (= MISS)
Investor Presentation filed with NSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹609.40
- Market cap
- ₹7,321 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 34.7×Sector 52.0×
- Promoter holding
- 40.19%+0.00% QoQ
- FII holding
- 12.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Earnings Call Transcript: Key Takeaways
Medplus reported Q2 revenue of ₹2,037.1 Cr with 21.3% pharmacy growth, but EBITDA margins were hit by state-mandated wage hikes.
- Call
- Guides 10% growth
Medplus Health Services Share Pledge
Catalyst Trusteeship pledged 34,00,000 Medplus Health Services shares (2.83%) as debenture collateral. Total encumbered shares rose to 2,41,50,400 (20.10% of capital).
Medplus Health Services Employee Stock Options
MedPlus allotted 19,095 equity shares to employees on exercise of ESOP 2021 options. Paid-up capital rises to Rs 24.03 Crore.
Medplus Health Services Q2 FY27 Results: Net Profit ₹56.1 Cr, Up 1.1% YoY
Medplus Health Services Ltd reported revenue from operations of ₹2,037 Cr (+21.3% YoY) and net profit of ₹56.1 Cr (+1.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.1 Cr · +1.1% YoY
Medplus Health Services Adverse Business Impact
Optival Health, a MedPlus subsidiary, had drug licences suspended at five Karnataka stores for 1–7 days. Expected impact is about Rs 8.66 lakhs.
- Value
- ₹0.09 Cr
- Execution
- 1 to 7 days per store
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary Optival Health faced temporary drug license suspensions for two stores by Mysore regulators. The estimated operational impact is ₹0.02 Crore.
- Value
- ₹0.02 Cr